Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Guard Therapeutics

1.64 SEK

+2.50 %

Less than 1K followers

GUARD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+2.50 %
-17.59 %
+11.56 %
+21.93 %
-92.90 %
-91.18 %
-97.20 %
-97.62 %
-99.90 %

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Read more
Market cap
33.07M SEK
Turnover
69.81K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.2
2026

Annual report '25

11.5
2026

Interim report Q1'26

18.5
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release2/5/2026, 3:45 PM

Guard Therapeutics Announces Changes to the Company’s Management Team

Guard Therapeutics
Press release2/5/2026, 3:35 PM

Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review

Guard Therapeutics
Press release1/15/2026, 3:55 PM

Guard Therapeutics Partners in EU Consortium For Alport Syndrome

Guard Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release12/30/2025, 1:20 PM

DNB Carnegie Access: Guard Therapeutics: Discontinuing coverage

Guard Therapeutics
Regulatory press release12/16/2025, 1:20 PM

Guard Therapeutics presents the Nomination Committee for 2026

Guard Therapeutics
Press release12/8/2025, 3:00 PM

Guard Therapeutics appoints Redeye as financial advisor in the strategic review

Guard Therapeutics
Regulatory press release12/5/2025, 1:40 PM

Guard Therapeutics changes Certified Adviser to Redeye AB

Guard Therapeutics
Press release12/5/2025, 5:21 AM

DNB Carnegie Access: Guard Therapeutics: Challenging path forward

Guard Therapeutics
Regulatory press release12/4/2025, 6:50 PM

Guard Therapeutics Explores Strategic Alternatives

Guard Therapeutics
Press release12/4/2025, 6:45 PM

Guard Therapeutics Provides Assessment of Full POINTER Study Results

Guard Therapeutics
Press release11/13/2025, 4:17 PM

DNB Carnegie Access: Guard Therapeutics: Awaiting further company communication – Q3 review

Guard Therapeutics
Press release10/27/2025, 8:33 AM

DNB Carnegie Access: Guard Therapeutics: POINTER data – endpoints not met

Guard Therapeutics
Regulatory press release10/26/2025, 10:45 AM

Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study

Guard Therapeutics
Press release10/17/2025, 6:00 AM

Guard Therapeutics to Present Late-Breaking Phase 2b POINTER Results at ASN Kidney Week 2025

Guard Therapeutics
Regulatory press release10/5/2025, 12:15 PM

Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study

Guard Therapeutics
Press release9/30/2025, 10:22 AM

DNB Carnegie Access: Guard Therapeutics: POINTER data preview: high risk, high potential reward - corrected version

Guard Therapeutics
Press release9/29/2025, 5:07 AM

DNB Carnegie Access: Guard Therapeutics: POINTER data preview: high risk, high potential reward

Guard Therapeutics
Press release9/11/2025, 3:10 PM

Guard Therapeutics announces completion of data collection in Phase 2b POINTER study

Guard Therapeutics
Press release9/11/2025, 8:46 AM

Redeye: Redeye Initiates Coverage of Guard Therapeutics

Guard Therapeutics
Press release9/2/2025, 2:24 PM

DNB Carnegie Access: Guard Therapeutics: DNB Carnegie’s Micro & Small Cap Day 2025 – highlights

Guard Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.